← All tickers

Is SLS Worth Buying in 2026?

SELLAS Life Sciences Group, Inc. Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-08-16

Here’s whether SELLAS Life Sciences Group, Inc. Common Stock (SLS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+6.21% over 10 days); strong 1-year return of +724.5%; 3-month momentum positive (+80.5%). Currently 19.5% off its 52-week high. Score: +6/7.

Ready to act on this? 📈 Trade on Webull

SLS is in a confirmed uptrend, trading above both its 50-day ($11.12) and 200-day ($5.89) moving averages. An RSI of 65.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +724.5% compares to +20.4% for SPY (beat the market by 704.1%).

$10,000 invested 1 year ago → $82,452 today
vs. S&P 500 (SPY) — same period beat market by 704.1%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✓Above 200-day MA ($5.89)
✓Above 50-day MA ($11.12)
✓RSI(14) neutral zone (30–70) — currently 65.5
✓Positive return (+724.5%)
!Within 10% of period high (−19.5%)
Period Range $12.78
$1.39 $15.88
RSI (14) 65.5
0 · OversoldOverbought · 100

Key Metrics

Price$12.78
Period Return+724.5%
Period High$15.88
Period Low$1.39
Drawdown−19.5%
MA-50$11.12
MA-200$5.89
RSI (14)65.5
Avg Volume (30d)6.8M
vs. SPYbeat by 704.1%
Return Rank#14 of 1252

Trade SLS

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers